Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life

Observational and Prospective Study in Patients With Nail Psoriasis Treated With Calcipotriene and Betamethasone Dipropionate Aerosol Foam to Evaluate the Change in the Severity of Psoriasis and in the Quality of Life

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04380597

Acronym

ENUPS

Enrollment

Registered

2020-05-08

Start date

2019-03-26

Completion date

2021-07-30

Last updated

2021-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nail Psoriasis

Brief summary

Observational, prospective and multicentre study to evaluate the effectiveness of calcipotriene and betamethasone dipropionate aerosol foam (Cal / BD), prescribed according to clinical practice and following the Product Data Sheet instructions, in the topical treatment of nail psoriasis according to the change in the score of the Nail Psoriasis Severity Index (NAPSI) at 12 weeks of treatment with respect to the initial score.

Interventions

DRUGCalcipotriene and betamethasone dipropionate aerosol foam

Prescribed according to clinical practice and following Product Data Sheet instructions

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patients with nail psoriasis who start, according to clinical practice, topical treatment with calcipotriene and betamethasone dipropionate aerosol foam * Patients who authorize their participation in the study by signing written informed consent.

Exclusion criteria

* Patients receiving treatment with systemic drugs or their prescription is scheduled for the next 3 months. However, may be included patients who receive the same systemic treatment regimen from at least 6 months before their inclusion in the study and up to 14 weeks later. * Patients with any situation or state that in the opinion of the investigator discourages their participation in the study.

Design outcomes

Primary

Measure	Time frame	Description
Nail Psoriasis Severity Index (NAPSI)	Baseline	Numeric, reproducible, objective, simple tool for evaluation of nail psoriasis

Secondary

Measure	Time frame	Description
Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA)	Baseline, Week 12 of treatment and Week 24 of treatment	Modular instrument for the assessment of clinical and patient-reported outcomes in nails.

Other

Measure	Time frame	Description
Hands Photographs	Baseline, Week 12 of treatment and Week 24 of treatment	High-quality photographs on patient´s both hands to document the psoriasis status

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026